EXOC3L1

Across TCGA pan-cancer cohorts, EXOC3L1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXOC3L1 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher EXOC3L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOC3L1 expression acts as an unfavorable survival marker.

UCS, DLBC, and CESC are the cancer types where EXOC3L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
CESC	OS	Median	II,III,IV	0.524	0.829	.006	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.317	0.626	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXOC3L1–UCS (OS)

Open the UCS breakdown →